Related Experiment Video
Updated: Sep 10, 2025

Quantifying the Antifungal Activity of Peptides Against Candida albicans
Published on: January 13, 2023
Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives
Francesco Branda1, Nicola Petrosillo2, Giancarlo Ceccarelli3
1Unit of Medical Statistics and Molecular Epidemiology, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
Abstract:
Invasive fungal infections (IFIs) represent a growing global health threat, particularly for immunocompromised populations, with mortality exceeding 1.5 million deaths annually. Despite their clinical and economic burden-costing billions in healthcare expenditures-fungal infections remain underprioritized in public health agendas. This review examines the current landscape of antifungal therapy, focusing on advances, challenges, and future directions. Key drug classes (polyenes, azoles, echinocandins, and novel agents) are analyzed for their mechanisms of action, pharmacokinetics, and clinical applications, alongside emerging resistance patterns in pathogens like Candida auris and azole-resistant Aspergillus fumigatus. The rise of resistance, driven by agricultural fungicide use and nosocomial transmission, underscores the need for innovative antifungals, rapid diagnostics, and stewardship programs. Promising developments include next-generation echinocandins (e.g., rezafungin), triterpenoids (ibrexafungerp), and orotomides (olorofim), which target resistant strains and offer improved safety profiles. The review also highlights the critical role of "One Health" strategies to mitigate environmental and clinical resistance. Future success hinges on multidisciplinary collaboration, enhanced surveillance, and accelerated drug development to address unmet needs in antifungal therapy.
Insights
Invasive fungal infections (IFIs) are a major global health crisis, causing over 1.5 million deaths annually. This review explores antifungal therapies, resistance challenges, and the urgent need for new treatments and strategies.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pharmacology
Background:
- Invasive fungal infections (IFIs) pose a significant global health threat, especially to immunocompromised individuals, resulting in over 1.5 million annual deaths.
- Despite substantial clinical and economic impact, IFIs receive inadequate public health prioritization.
- Antifungal resistance is an escalating concern, driven by factors including agricultural fungicide use and healthcare-associated infections.
Purpose of the Study:
- To review the current state of antifungal therapy, encompassing recent advancements, persistent challenges, and future research directions.
- To analyze existing antifungal drug classes and investigate emerging resistance patterns in key fungal pathogens.
- To highlight novel therapeutic agents and the importance of integrated strategies for combating antifungal resistance.
Main Methods:
- Comprehensive literature review of antifungal agents, mechanisms of action, pharmacokinetics, and clinical utility.
- Analysis of current and emerging antifungal resistance trends, focusing on pathogens like *Candida auris* and resistant *Aspergillus fumigatus*.
- Examination of novel antifungal drug candidates, including next-generation echinocandins, triterpenoids, and orotomides.
Main Results:
- Established antifungal drug classes (polyenes, azoles, echinocandins) are discussed alongside their limitations and the growing challenge of resistance.
- Emerging resistance in critical pathogens like *Candida auris* and azole-resistant *Aspergillus fumigatus* necessitates urgent intervention.
- Promising novel agents such as rezafungin, ibrexafungerp, and olorofim demonstrate potential against resistant strains and improved safety profiles.
Conclusions:
- Addressing the escalating threat of IFIs and antifungal resistance requires innovative therapies, rapid diagnostics, and robust stewardship programs.
- Integrated
- One Health
- approaches are crucial for mitigating resistance across environmental and clinical settings.
- Multidisciplinary collaboration, enhanced surveillance, and accelerated drug development are essential to meet the unmet needs in antifungal treatment.
Related Concept Videos
Antimicrobial Effectiveness
Microorganisms in Medicine and Therapeutics
Overview of Fungi
Fungal Phylum Ascomycota
Fungal Phylum Microsporidia
Chemical Agents for Microbial Control

